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Abstract: Healthcare spending is nowadays one of the key issues of 
healthcare system practice as its share in GDP has constantly increased 
during past decades, which is now above 10% of GDP in developed 
countries. However, very often it is more of an issue related to the 
current political and socio-economic situation in a country rather than 
the one managed by experts. Although one might expect that the 
increase in healthcare spending contributes to better health of the 
population, relevant indicators show that high healthcare spending in 
Bosnia and Herzegovina (BiH) does not result in better health of its 
population. Due to this reason, special attention needs to be paid to the 
economic analysis of healthcare spending. Irrational use of medications 
is just one of many problems associated with an inefficient health 
system, but one that heavily impacts on the health economics. In 
situations where it may not be easy to change the existing financing 
models, we should explore how to be more effective in spending within 
the existing structure. Better control of medication consumption could 
be one of the actions that helps improve the effectiveness of the 
available budget. Therefore, the general aim of the paper is to 
determine the effect that financial monitoring of medication 
consumption has on the control of increase in healthcare spending, 
which in turn might help establishing a financially sustainable 
healthcare system. Bearing in mind that irrational usage of 
medications influences the access to healthcare services, destabilizes 
country’s budget, and endangers the margin of social sustainability 
(endurance), the constant financial monitoring of medication 
consumption is important as it can help us recognize those segments 
where consumption deviates from standard and where prevention 
activities are needed. All this can result in the limitation of further 
increase in medication consumption. 
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Introduction 
 
Health is an economic potential, a segment of human capital that increases 
productivity and reduces treatment costs. However, in no way is health a free 
resource and it cannot be maintained without incurring costs. High quality 
healthcare protection is the most cost effective investment into human capital.  
 
The need for healthcare is unpredictable, sudden and unexpected, and it is in 
society’s interest to recognize the real need for healthcare services. The characteristic 
of healthcare spending is that the consumer of healthcare goods, as a rule, is 
incapable of assessing their value. Unlike other goods, healthcare protection is 
specific, primarily due to the basic economic laws acting in the field of healthcare. 
The laws of demand and supply of healthcare services function in a specific market 
that includes several mutually related markets such as the market for various types of 
insurance (compulsory, additional) or different levels of treatment (outpatient 
clinics, polyclinics, hospitals), labor market for healthcare workers, market for 
medications, medical equipment, and so on. On the demand side, there are 
indicators of population health while on the supply side there are indicators of 
healthcare resources. When establishing the efficiency of healthcare market aimed at 
providing efficient healthcare protection for every citizen, the key role is given to the 
economic effects of deciding on the rational usage of ever limited financial resources.  
 
From the macroeconomic point of view, the healthcare system creates a significant 
burden on any economy – rich or poor, so limiting the increase in healthcare 
spending is very important for everyone. Growing costs, irrational behavior, and 
dissatisfaction in the healthcare system are self-evident, with the main reasons for 
increased spending being: increased share of the elderly persons in the entire 
population, increased number of patients with chronic diseases, introduction of new 
medications (which, as a rule, are more expensive), influence of the pharmaceutical 
industry, growing pressure exerted by patients, and easy access to medications. 
Establishing the financial sustainability of healthcare system is by no means an easy 
task, which is why the healthcare system needs to be perceived from the economic 
perspective (the so called health economics). On the one side, some authors believe 
that the financing of healthcare needs to be changed so that the system becomes 
sustainable in the long run, while others think that the reduction of healthcare costs 
is needed. When it comes to the efficient functioning of the healthcare system, the 
economic analysis is given prominence over other types of analysis specific for the 
market of healthcare services. 
 
Financial Monitoring of Medication Consumption in Bosnia and Herzegovina	  
	  
7 Volume 7  | Issue 1 |  
Health economics always starts with the assumption that healthcare services can be 
analyzed as any other market activity. However, the process often ends in the 
explanation why the market activity fails to lead to the efficient resource allocation in 
healthcare. Economic analyses of healthcare spending in BiH are poorly represented 
partly due to the lack of full scale data and their transparency and partly due to a 
relative lack of economic experts’ interest in the research on health economics. The 
increase of financial resources in the healthcare sector cannot be expected and the 
room for savings which will not negatively affect the quality of healthcare protection 
needs to be identified. The starting point of discussion in BiH is the aspiration that 
the access to healthcare is universal, just, equal for all, and basically “free”. However, 
healthcare costs are constantly on the increase and in the last ten years they have 
been growing at an unsustainable rate. For example, in 2003, the total per capita 
healthcare spending in BiH Federation was BAM 345 while the amount per an 
insured person was BAM 417.1  According to the latest available data, in 2012 the 
total per capita healthcare spending reached the level of BAM 714 while the amount 
per an insured person was BAM 825 (Health Insurance and Reinsurance Fund of 
BiH Federation, 2013). The average spending per an insured person in Republic of 
Srpska in 2012 was BAM 714 (Health Insurance Fund of Republika Srpska, 2013). 
 
The problem of monitoring healthcare spending in BiH is rather serious as there is 
no centralized system of monitoring spending on the state level. Monitoring is 
additionally complicated by the current administrative organization of the healthcare 
system. The data on healthcare are scarce and they are not systematized and unified. 
This is supported by the fact that BiH was first included in the European Health 
Consumer Index in 2014 and was positioned last due to an enormous lack of data 
on its healthcare protection, receiving 420 out of 1,000 points, less than Albania, 
Serbia, and Montenegro (Björnberg, 2015). 
 
Medications are one of important items in the total healthcare spending. With 
limited financial resources, increasing medication consumption directly influences 
the access to healthcare services, destabilizes country’s budget, and endangers the 
margin of social sustainability (endurance). Medication consumption in world’s total 
healthcare spending is placed third, with 17%.  
 
This paper brings the analysis of potential control of medication consumption and 
the financial aspect of medication consumption monitoring aimed at the reduction 
of healthcare spending. The main research hypothesis is postulated as follows: 
“Financial monitoring of medication consumption can contribute to the 
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rationalization of medication consumption, reduction of healthcare spending, and 
the efficiency of the entire healthcare system.” Although the paper focuses on the 
healthcare system in BiH, some results and recommendations can be generalized and 
are potentially universal, taking into consideration the recent global socio-economic 
events (increased share of the elderly persons in the entire population, increased 
number of patients with chronic diseases, increased public expenditure following the 
crisis in 2008, slow economic growth, and so on). 
 
Review of Previous Research on Health-Related Spending 
 
Medications are third most common cause of mortality in the USA and Europe, 
following heart diseases and cancer. Patients trust their physicians and physicians 
trust the pharmaceutical industry although these relations are not free from 
difficulties (medication testing is sometimes inadequately conducted, for example). It 
is expected that medication allocations are to increase in the comming years. The 
USA data indicate that direct costs of cardiovascular diseases would triple between 
2010 and 2030, from USD 273 billion to 818 billion, while indirect costs would 
increase in the same period by 61%, from USD 172 billion to 276 billion (Vitezić, 
2013, p. 246-251). The annual number of deaths in the European Union (EU) 
resulting from patients’ not taking medication correctly or not cooperating with 
their physicians was 194,500, which costs the EU the amount of EUR 125 billion a 
year (Pharmaceutical Group of the European Union, 2012). 
 
Decreased spending in healthcare requires the checks and controls of executed 
interventions and diagnostic and therapeutic services as well as the checks of whether 
they are really needed. That is why a unified system of expense list needs to be made 
that would include five important categories: hospitals, prescription-only medicines, 
diagnostic procedures, treatment costs, and home treatment costs (Ott et al., 2000). 
 
Polić-Vižintin, Tripković, Štrban-Štok, Štimac, and Čulig (2006) analyzed 
healthcare indicators and non-hospital medication consumption by using the data 
gathered from the vital statistics and healthcare-statistics research. They concluded 
that in order to rationalize medication consumption, treatment should be focused on 
primary healthcare protection, which is why constant education of family doctors 
needs to be made regarding proper therapy based on professional guidelines. As 
specified by the EU/WHO Working Group (2008), the primary healthcare 
protection, as a rule, should be able to solve at least 80% of all health problems. 
Gajski (2009), for example, stated that most medications prescribed for the 
treatment of cardiovascular diseases in Croatia are actually unnecessary and serve for 
the medicalization of the society and the profit of pharmaceutical company with 
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pharmaceutical therapy costs in Croatia amounting to some HRK 7 billion, which is 
a waste of money. 
 
Vlahović-Palčevski (2000) stated that the analysis of medication consumption gives 
us the data on the rationality of their use, indicates the segments where efforts should 
be made so as to improve the current situation, and tells us about therapy tradition, 
irrationalities, and abuse. Monitoring and analyzing medication consumption was 
the main reason for the development of the so called ATC (Anatomical, 
Therapeutic, and Chemical)/DDD (Defined Daily Dose) methodology. It was 
proved useful for the comparison of medication consumption at a national and 
international level as well as for long-term evaluation of consumption. A study 
conducted some 20 years ago by the Drug Utilization Research Group (DURG) 
showed the lack of universal methodology of medication consumption monitoring, 
which preceded the establishment of a unique Anatomical Therapeutic Chemical 
(ATC) classification system. This resulted in the introduction of defined daily dose 
as a statistical unit for medication consumption monitoring instead of packages, 
prescriptions, and financial units, which allowed for a detailed analysis of medication 
consumption (Čulig, 2004).  
 
Polypragmasy (i.e. parallel application of three or more medications) is recognized as 
an increasingly serious problem in the existing systems of healthcare protection. It 
can increase the complexity of healthcare protection and its costs. Apart from the 
elderly persons, some groups of patients have a higher risk of polypragmasy, such as 
psychiatric patients and patients who constantly take five or more types of 
medications, patients treated by several physicians, recently hospitalized patients, 
patients with concurrent comorbidity, patients with lower education, visually 
impaired patients or those with decreased physical activity and ability in daily 
activities. Polypragmasy is indicated as one of the main problems in modern world 
pharmacotherapy and its solutions require the education of both physicians and 
patients.2 Regular analysis of prescription issuance practice proved to be efficient in 
reducing unnecessary medications. A study in which the patients brought all the 
medications they use, with their physicians being given directions on polypragmasy, 
resulted in 42% of the patients being under the risk of polypragmasy, for 20% of 
them the medication use was suspended and for 30% of them the medication dose 
was changed. In addition, pharmacists sent the list of medications to the physicians 
whose patients use potentially harmful medications, which reduced the issuance of 
prescriptions by 12.5%. Furthermore, consulting a clinical pharmacologist reduced 
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polypragmasy and the number of medications from 7.9 to 4.1/1000 cases (Kašuba 
Lazić, 2015). 
 
Monitoring and control of medication consumption is also important from the 
aspect of environment protection as medication residues are often found in the 
environment in small concentrations. During the procedure of authorization of a 
medication, most regulatory agencies specify the assessment of potential risk that a 
medication can make on the environment (Čogelja Čajo et al., 2010). 
 
The amount pharmaceutical companies spend on physicians is still not precisely 
known. However, according to the financial reports of nine leading US medication 
manufacturers, this amount is estimated to be dozens of billions of US dollars a year. 
This actually means that the pharmaceutical industry strictly regulates the ways their 
medications are prescribed and this includes not only physicians but also university 
professors that affect research results, medical practices, and even disease definition 
(Angell, 2009). The research conducted by Consumers International, the 
international organization for consumer protection, showed that pharmaceutical 
companies spend twice as much on persuading physicians to prescribe their 
medications than on researching new medications (Republic of Serbia Anti-
Corruption Agency, 2012). 
 
In 2011, with the assistance of the World Bank (WB), aimed at increasing 
transparent prices of medications in BiH, a survey was made into the retail sale prices 
at pharmacies for 36 frequently used medications. The selected medications included 
essential medications used for frequent diseases (cardiovascular diseases, nerve 
diseases, diabetes, and respiratory diseases). The data were collected from 82 
pharmacies randomly selected in eight cantons/regions in the entire BiH. It became 
evident that brand name medications are not common in BiH as they were 
registered in only 27% of the cases, which is why the data refer primarily to generic 
medications (WB, 2012). 
 
Good practice in creating and managing sustainable healthcare system is evidenced 
by Singapore with excellent results in high quality of its healthcare system and in 
control of healthcare protection costs. The per capita cost of healthcare protection in 
that country or the cost of healthcare protection presented as the GDP percentage is 
lower than in all high income countries in the world. There are three crucial reasons 
for achieving available excellence − first of all, long-term political unity, then the 
ability to recognize and establish national priorities, and finally constant aspiration 
for collective welfare and social harmony in the country (Haseltine, 2013).  
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The importance of reliable data and information is confirmed by Benković (2009), 
who aimed at checking whether the results of the research conducted by the 
Croatian Health Interview Survey (CHIS) were used in planning the resources at the 
level of country’s public health institutes. The usage of reliable data and information 
that serve as the basis for making fiscal and strategic decisions is the main support in 
healthcare management. It is also the key to strategic management that uses 
necessary information needed for setting the focus, selecting priorities, and 
establishing good “macro policy at the micro level”. The results showed that only 
32% of the subjects used the results of the CHIS in their plans, which led to the 
conclusion that such a percentage would make efficient local level planning and 
planned budget savings difficult to achieve. Recognizing the importance of using 
data such as those collected by the CHIS is an extremely important factor in local 
and national healthcare planning and the factor that enables significant budget 
savings in healthcare. 
 
Ott, Kesner-Škreb, Bajo, Bejaković, and Bubaš (2000) underlined that even though 
healthcare and health insurance reform is not easy to implement, potential changes 
aimed at the improvement of health and healthcare are multiple while costs would 
be significantly lower than potential savings. The reform of the existing health 
insurance system directed towards higher reliance on private insurance and 
strengthening market elements is required for the long-term sustainability of the 
system. Consequently, it might reduce the excessive role of the state, limit its 
paternal behavior, and create the conditions for income increase. 
 
Theoretical Framework of Medication Consumption Monitoring and its 
Financial Aspect, with the Focus on Bosnia and Herzegovina 
 
Healthcare is one of the most complex systems in every country and it is a sub 
system of the entire socio-economic system. Its organization functionally consists of 
(Salihbašić, 2009): 
• Primary healthcare that includes outpatient clinics; 
• Polyclinics, general and specialized hospitals, specialized institutes, medical centers; 
• Other institutions including public health institutes, emergency rescue teams, and 
pharmacies. 
 
The main problem in this field is financing. Several models of financing are used in 
the world, the most known being (Salihbašić, 2009): 
• The Bismarck model, which functions on the principle of solidarity and 
reciprocity, as is the case with BiH; 
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• The Beveridge model by which healthcare is financed through taxes paid by 
citizens (for example, Great Britain, Norway, Sweden, Ireland); 
• The Semaškov model emerged in the Soviet Union and was provided for the entire 
population. Insurance is financed from the central state budget whereby the 
government is responsible for making decision on the rights and obligations of the 
insured persons. As a rule, this means that healthcare protection is free although 
there is the problem of users having excessive expectations without additional 
payments. Nowadays, this model is present is some Asian countries (China, 
Mongolia, North Korea, Vietnam) and in Cuba; 
• Private financing that includes the basic insurance with the payment of additional 
insurance according to individual needs and purchasing power.  
 
The cost assocated with the healthcare sector is significant from the macroeconomic 
point of view, so the limitation of increase in healthcare spending is particularly 
important as the increasing healthcare spending is a burden to both developing and 
developed countries. Growing costs, irrational behaviour, and dissatisfaction within 
the healthcare system are self-evident and the main reasons for increased spending 
are: increased share of the elderly persons in the entire population, increased number 
of patients with chronic diseases, introduction of new medications (which, as a rule, 
are more expensive), influence of the pharmaceutical industry, growing pressure 
exerted by patients and easy access to medications.  
 
It is important to note that, while medication consumption is one of the main 
generators of healthcare spending, it is also the item that could be more easily 
controlled and rationalized. The increase in pharmaceutical costs raises the issue of 
possibile need for financing healthcare systems in the future. Every country should 
be be interested in protecting itself against uncontrolled increase of medication 
spending, aiming to reduce it and make it more rational. Providing the population 
with high quality, safe, and efficient medications that would be rationally used is 
only one of the basic goals of every healthcare system. Hence, one of the measures 
for rational spending on medications is a systematic (national) policy of medication 
consumption monitoring as well as creation of a unique information system that 
would integrate all the data relevant for medication consumption, from both 
hospitals and non-hospital institutions, including the data on individual medication 
consumption.  
 
However, BiH has a fragmented internal organization with centralized Republic of 
Srpska (RS), decentralized BiH Federation (F BiH), and Brčko District, which 
further complicates successful conduct of fiscal policy. This leads to an unsatisfactory 
level of efficiency in improving country’s economic growth. As reported by the WB 
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(2014), the potentials of BiH economy for mid-term growth are limited by poor 
business environment that still requires essential reforms and prevents investment 
and growth, with the fiscal policy still focused on the distribution of revenue rather 
than growth.  
 
Healthcare and health insurance system in F BiH is, pursuant to the Constitution 
and legal regulations, based on the principles of shared competence between the 
federal and cantonal authorities. Pursuant to the provisions of Law on Healthcare3, 
Law on Health Insurance 4 , and other acts based on these laws, the federal 
government is in charge of creating the policy and adopting laws while the cantonal 
government implements laws and establishes and adapts cantonal healthcare policy 
with the policy at the level of F BiH. Cantonal public health institutes function with 
difficulties, healthcare spending increases while the structure of the insured persons is 
unfavorable.  
 
Similar to other South East European countries, BiH has the model of social 
insurance with employees and employers paying contributions to the public health 
funds which finance the majority of healthcare services. That is why healthcare 
financing heavily relies on salary taxation and the capacities of tax authorities to 
collect payments5.  The existing model of healthcare financing in BiH is based on 
the past times as the remnants of the Bismarck model. Healthcare insurance 
contributions were never a part of the state budget but were directly paid to health 
insurance funds. The contributions for compulsory health insurance are based on the 
taxation of the amounts registered in the pay sheet rather than by health insurance 
premium or general taxation.   
 
The healthcare sector in BiH does not function on economic prices but on the 
solidarity system that implies that the rich show their solidarity with the poor, the 
young with the old, the healthy with the sick, and individuals with the family. This 
is what makes the total income of the Health Insurance and Reinsurance Funds 
which stand for the main source of funding for healthcare protection in both BiH 
entities. What is evident in the healthcare system is a rather non-transparent flow of 
resources between different non-budget funds that are supposed to pay contributions 
on behalf of their users (pensioners, registered unemployed persons) and the limited 
government contributions on behalf of some users exempt from paying 
contributions. Consequently, the state invests, or is supposed to invest, extreme 
efforts to provide as efficient healthcare protection as possible for its users with the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Official Gazette of BiH Federation No. 46/10 
4 Official Gazette of BiH Federation No. 30/97, 07/02, and 70/08 
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available resources. Even though it sounds easy, it is very difficult to implement this 
in practice.  
 
Looking at the data on some financial indicators in BiH, one can notice a very high 
share of healthcare spending in GDP when observed in the context of the economic 
development of the state. Healthcare-related public spending is constantly on the 
increase; in 2002 it was 62.5% while in 2012 it was 71.1% of the total healthcare 
spending. On the other hand, social health insurance has a downward trend while 
private health insurance, present since 2009, has a very low percentage of 0.8% to 
1% of the total health insurance. The very fact that some ten years ago, per capita 
spending was USD 122 and that the number increased to USD 447 in 2012 
indicates that healthcare system becomes more expensive year after year. 
 
From the traditional aspect of efficiency, safety, and quality as well as from the 
aspect of financial cost effectiveness, medication consumption monitoring in 
developed countries started 40 years ago, mainly due to the fact that the funds for 
these purposes are always limited and the needs are increasingly higher. A constant 
lack in financial resources is registered in all spheres of life and in the healthcare 
protection system in particular. New medications, development of medical 
technology, new methods of treatment, constant education and training of 
healthcare workers, introduction of information systems, and so on, all require 
additional resources that are almost always limited. The country is given a serious 
task – to provide additional resources when the current ones are insufficient even for 
the present costs of healthcare protection.  
 
In addition, increased number of patients suffering from various diseases of modern 
times (such as cardiovascular diseases, cancer, diabetes) results in increased need for 
medications. Medication consumption has been rapidly growing for years, which is a 
problem threatening sustainable and stable financing of the healthcare system. A 
systemic approach to this problem is not evident in practice since mentioning 
finances in the context of health and treatment is considered inappropriate and 
unethical. Besides, the issue of pharmacotherapy has escalated recently, when it 
reached the level the society cannot bear. Moreover, medication manufacturers that 
are highly influential in the medical science, education, politics along with the media 
have no interest in putting this topic in the discussion focus (Gajski, 2009). 
Prescribed medications cover 10% to 20% of the total healthcare costs and are the 
fastest growing segment of the total spending, which raises concerns over medication 
consumption. In order to resolve this issue, we must first discuss the potential causes 
of the increase in medication consumption.  
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One of the reasons of increased medication consumption is definitely medication 
abuse which can cause various side effects, resulting in the need for additional 
treatment and reflecting on the increase in healthcare spending. According to the 
World Health Organization (WHO, 2008), in some countries the costs of 
medication side effects, including hospitalization, surgeries, and lost productivity, are 
higher than medication costs.  
 
Also, the studies conducted on the territory of the EU showed that some 200,000 
people die every year due to nonadherence (not taking the prescribed therapy or 
taking it inappropriately). Annual nonadherence costs in the EU amount to EUR 
125 billion and they include the treatment of chronic disease complications as a 
consequence of not taking medications. Low adherence for the patients suffering 
from hypertension correlates to the increased risk of vascular diseases, 
hospitalization, and increased costs of healthcare protection, while a higher level of 
adherence for the patients suffering from hypertension results in better health of 
individuals and net economic profit (Dragomir, 2010). Adherence reduces the total 
annual healthcare spending for the patients with chronic vascular diseases by the 
lower number of hospital days and lower hospital costs. The effects of adherence are 
more evident for the patients over the age of 65 (Roebuck et al., 2011).   
 
Very often, influenced by marketing activities of the pharmaceutical industry, 
patients purchase medications on their own and increasingly use alternative 
medicine. Consequently, medication becomes a merchandise article and medication 
prescription becomes a routine activity made in silence with very little written or oral 
information provided (Stević et al., 2011). Besides, inappropriate package of certain 
medications can result in increased financial spending, mainly due to the package 
content which does not correlate with the length of treatment. This could be easily 
overcome if physicians prescribed the exact quantity needed for therapy treatment 
and if pharmacies would supply medications per piece. 
 
One of the specific features of BiH medication market is related to the conditions 
under which pharmacies function. The legal regulations, among other things, cover 
pharmacy margins – maximum up to 8% for wholesale and up to 25% in retail sale6.  
Very often, retail sale margins go above the highest limit and are as much as 30%. It 
seems that this is still not enough for pharmacists as they mainly dealt with this issue 
at the meeting held at the beginning of 2016. One of the suggestions was that the 
margin increases to the record high 40%, which is not in accordance to the legal 
regulations. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 Rulebook on Medication Wholesale and Retail Sale Margin, Official Gazette of BiH Federation No. 40/02, 50/02, 
15/06, and 9/08 
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The Rulebook on Price Monitoring, Calculating Medication Prices and Reporting 
on Medication Prices in BiH7 would be an excellent instrument for monitoring 
medications in BiH, which seems to be inoperative in practice. As recommended by 
the WB, the new rulebook on regulating medication prices is under preparation, 
which, if strictly followed, could lead to significant savings. Medications are cheaper 
in RS than in F BiH, mainly due to the centralized system of medication 
procurement, which allows for lower prices. Although the F BiH Government is 
under pressure to reduce medication costs, pharmacists are of the opinion that the 
government should “cut the costs” in other segments, such as waiving the value-
added tax (VAT) on medications instead of reducing pharmacy margins. It was 
stated that some reductions would amount from 25% to 30%, which, as claimed by 
the pharmaceutical chambers, pharmacies would not be able to bear. Major 
dissatisfaction was expressed as the representatives of professional associations were 
not given the opportunity to comment the proposed wording of the rulebook. They 
clearly rejected to support the proposal that Serbia be the reference country for 
establishing the prices of pharmaceutical services as the prices in that country are 
specified through administrative procedures. The representatives of professional 
pharmaceutical associations agree that the medication market needs to be regulated 
but not by replicating the experiences of other countries without taking into 
consideration the specific characteristics of the medication market in BiH.8  
 
Many European countries introduced a series of measures to combat the growth of 
pharmaceutical spending. Some of these measures include reduction of prices of 
pharmaceutical products, which can be achieved through negotiations with 
pharmaceutical manufacturers, reduction of pharmaceutical margins, introduction of 
quotation price, application of obligatory discount, reduction of VAT on 
pharmaceutical products, centralized public procurement of pharmaceutical 
products, promotion of usage of generic medications, increase of obligatory 
contribution for households, and so on. For example, as of 2010 Spain has 
introduced a general discount applicable to all the medications prescribed, after 
which it introduced the mandate for the reduction of generic medication prices, 
which is certainly one of the factors that explains the increase in the consumption of 
generic medications in that country. In Germany, the obligatory discounts for 
manufacturers were raised in 2011 and the prices were frozen until 2013. As of 
2011, pharmaceutical companies are obliged to negotiate with health insurance 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 Official Gazette of BiH No. 82/11 
8 The minutes of the meeting of the presidents of cantonal pharmaceutical chambers, the Pharmaceutical 
Association in BiH Federation, and general managers of larger pharmaceutical healthcare institutions in BiH 
Federation. Retrieved from  http://www.farmaceutisarajevo.ba/index.php/25-obavijesti/89-sastanak-farmaceuta-u-
sarajevu dan posjete 
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funds about innovative medications, which ended the former free pricing regime. 
The reduction of consumption in Italy can be attributed to a rather reduced budget 
for pharmaceutical products per Italian regions as well as to the reduced 
pharmaceutical wholesale margins and lower prices of generic medications based on 
quotation prices. The introduction of new obligatory public offer procedures for 
medication procurement in Hungary resulted in reduced costs, while in Denmark, as 
in many other countries, the negative trend can be explained partly due to the 
expiration of patents for large scale protected medications and very expensive 
medications (OECD & the European Commission, 2014). 
 
Methodology of the Empirical Research: The Case of Tuzla Canton, 
Bosnia and Herzegovina 
 
The sources used for this paper include the publications and statistical data of the 
relevant international and domestic organizations (WHO, WB, EUROSTAT, 
OECD, Agency for Medicinal Products and Medical Devices of BiH, Agency for 
Statistics of BiH, Health Insurance and Reinsurance Fund of F BiH, Health 
Insurance Fund of RS, Health Insurance Fund of Brčko District, Institute for Public 
Health of F BiH, Institute for Public Health of RS, and Health Insurance Fund of 
Tuzla Canton). Based on these sources, the paper presents selective and relevant 
macroeconomic and healthcare indicators for BiH as well as the basic indicators of 
healthcare financing and healthcare spending in BiH. More specifically, the focus is 
made on the elaboration of detailed parameters of medication related spending in the 
most populated BiH canton – Tuzla Canton – so as to obtain a clear view of 
medication consumption and its potentially influential factors. In order to achieve 
this, we opted for using the ten year period data (2004-2013), which allowed for the 
summary of the data and their comparison with the previous periods. 
 
Results and Discussion 
 
The medication market in BiH is worth over BAM 500 million, out of which 18% 
belongs to domestic medication manufacturers. The data on the leading medications 
in the total turnover cannot be regarded as relevant as it is known that medication 
consumption in BiH is not monitored by the standardized ATC/DDD 
methodology. Since medication prices vary and are rather different when compared 
to the neighboring countries, we do not have the appropriate data on the actual 
consumption of medications but rather the amount specified in the budget. 
Medication consumption in RS is monitored by the ATC/DDD methodology, 
which is not the case in F BiH. For example, “Pantoprazol” is the leading medication 
in the total turnover in BiH (some BAM 11 million) and its price in F BiH is 
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around BAM 15 while at the same time its price in the neighboring Serbia is BAM 
3.5. The similar situation is with the frequently prescribed medications such as those 
for the treatment of cardiovascular diseases.  
 
The WB (2014) also pointed to the unbalanced prices of medications in BiH in 
comparison to the neighboring countries, which is particularly evident for the 
medications for frequent diseases (see Table 1). For example, the medications for 
cardiovascular diseases are up to 200% more expensive than in Croatia and even 
more than in Serbia. The main reasons for such situation are the inefficient system of 
pricing and purchasing medications, a non-transparent system of pricing for 
individual medications as well as rather fragmented system of medication 
procurement which results in different prices in cantons. As stated in the report, the 
Ministry of Health of F BiH is not able to force the cantons to follow the regulations 
when they create the positive lists of medications. 
	  
Table 1. Prices of Sampled Medications in FBiH and Serbia in 2016 
Ordinal 
number 
Medication Manufacturer Package 





Serbia9 F BiH10 
1 
Vesicare - symptomatic 
treatment of immediate 
incontinence 
Astelles Pharma Europe 
B.V Holland 
5 g (30 pills) 59 79 33.90 
2 Nimulid – painkiller 
PANACEA BIOTEC 
LTD. India 
100 mg (20 pcs) 3.3 7 112.12 
3 Letrox -thyroid hormone 
BERLIN-CHEMIE AG 
Germany 
100 mg (100 pcs) 5.2 8.5 63.46 
4 
Atoris -cholesterol lowering 
medicine 
KRKA dd Slovenia 20 mg (30 pills) 8.5 14.6 71.76 
5 




40 mg (28 pcs) 3.6 15.5 330.56 
6 Tritace - ACE inhibitor 
Sanofi-Aventis S.p.A. 
Italy 
5 mg (28 pills) 3.4 10.5 208.82 
7 
Lorista – hypertension 
treatment 
KRKA dd Slovenia 50 mg (28 pills) 5 11 120.00 
8 
Roswera - cholesterol lowering 
medicine 
KRKA dd Slovenia 40 mg (28 pills) 16 35 118,75 
9 




2% (5 ml) 12 20 66.67 
10 




75 mg (28 pills) 10.5 32.5 209.52 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 Prices as indicated in the price list of the pharmacy “Zdravlje 2ˮ, Mali Zvornik, Serbia, May 15-June 15, 2016 
10 Prices as indicated in the price list of the pharmacy “Ibn Sinaˮ, Tuzla, on June 16, 2016 
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11 
Trimetakor –prevention of 
angina pectoris attacks 
Cipla Limited India 35 mg (60 pcs) 4.5 19.8 340.00 
12 Byol – hypertension treatment Lek dd Slovenia 5 mg  (30 pills) 3.5 13.2 277.14 
Source: Authors' research based on selected BiH and Serbian pharmacies price lists 
 
There is no unique, state-level system of medication consumption monitoring 
(including commercial medications as well as those prescribed in the compulsory 
health insurance), except for the health spending data created by the national health 
accounts methodology. It is known that in 2013, the costs of medicinal devices for 
non-hospital patients (including medications) were BAM 711,221 million, of which 
public expenses amount to 43.2% and private expenses amount to 56.68%, which 
indicates rather high payments made by citizens for this type of medicinal devices. 
Analytically speaking, it is not known how much of this amount is spent on 
medications charged to health insurance, be they commercial or those given on 
prescription.  
 
Healthcare spending of F BiH makes 10.2% of GDP, out of which a quarter, 
somewhat over BAM 416 million, is used for medications. Over BAM 182 million 
was spent on medications charged to health insurance, which makes around 11% of 
the total healthcare spending. On average, a citizen of F BiH spends around BAM 
178, while the insured person spends BAM 90 on prescribed medications, somewhat 
less than in RS where an insured person spends BAM 99. The average consumption 
of prescribed medications per cantons in F BiH in 2013 ranged from BAM 46 in 
Posavina Canton to BAM 167 in Sarajevo Canton, which implies huge cantonal 
differences in the rights of insured persons to prescribed medications. The average 
consumption of prescribed medications is a relative indicator for F BiH as it is highly 
influenced by a huge average consumption in Sarajevo and Tuzla Cantons. Although 
the prices of most prescribed medications show a downward trend, the increased 
consumption of prescribed medications is partly caused by the facts that cantonal 
medication lists are harmonized with the federal essential list of medications and that 
some cantons have more medications on their lists than on the one made by F BiH. 
Although Sarajevo Canton has by 78% higher consumption of medications per 
insured person than Tuzla Canton, when the total healthcare spending per cantons is 
observed, consumption of medications as a part of healthcare spending is the highest 
in Tuzla Canton as it is the most populated one. 
 
The leading cause of death in Tuzla Canton is essential hypertension (86/100,000 
people). Stroke, cardiomyopathy, acute myocardial infarction, essential 
hypertension, cardiac arrest, and chronic heart ischemic disease make 71% of the ten 
leading causes of death in Tuzla Canton. In total, the population in 2013 suffered 
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from acute infections of upper respiratory tract, hypertension, acute bronchitis and 
bronchiolitis, diabetes, and spinal diseases. Diseases in the primary healthcare follow 
hospital treatment data in Tuzla Canton, where five leading diseases make for 
56.79% of the total number of hospital days. Some of the most often prescribed 
medications by the ATC classification are those for cardiovascular diseases, digestive 
tract and metabolism, nervous system, and medications for the treatment of system 
infections and respiratory system, which indicates that cardiovascular diseases, 
metabolic disorders, and respiratory diseases are the major health problems in Tuzla 
Canton. In the last ten years, there has been an increase in the number of patients 
suffering from circulatory system diseases, diabetes, cancer, and mental disorders 
(Table 2). This increased number of patients causes higher healthcare costs and 
consequently increased medication consumption. The treatment of these diseases, 
except for cardiovascular diseases, requires the medications that belong to a group of 
more expensive medications, which is why the growth of financial spending does not 
come as a surprise. 
 
Table 2. Types of Diseases and Number of Patients in Tuzla Canton 
Number of patients in Tuzla Canton since  
Year 
Increase in % 
2004 2013 
Circulatory system diseases 47,705 75,234  57.7 
Diabetes 7,488 16,952 126.4 
Malignant neoplasms 1,947 4,194 115.4 
Mental disorders 11,552 19,207   66.3 
Source: Authors' research based on Institute for Public Health of Tuzla Canton database 
 
Generally speaking, medication consumption increases year after year, including 
both commercial as well as prescribed medications charged to health insurance. The 
increased costs of commercial medications point to the fact that citizens invest more 
of their personal resources to purchase medications, even though essential lists of 
medications for cantons have been expanded.  
 
Medication consumption monitoring in Tuzla Canton is administered by the Health 
Insurance Fund and it includes the data basis that includes the information on 
insured person (national ID number), medication, authorized physician, outpatient 
clinic where the prescription was issued, prescription, contracting pharmacy where 
medication was taken, date of prescription issuance and individual invoice for 
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medication/prescription issued by the number and date of invoice,11 but not the 
ATC/DDD methodology, as recommended by the WHO.  
 
In the period 2004-2013, health insurance expenditures constantly increased. By 
analogy, expenditures grew in all segments of healthcare protection, especially for the 
program of medications charged to the Health Insurance Fund of Tuzla Canton 
(HIF TC), as it is shown in Table 3. The total health insurance expenditures grew 
over the period of ten years by 85.55%, from BAM 244 to BAM 439 per insured 
person.  
 
Table 3. Review of Financial Expenditures for the Program of Medications in Compulsory 
Health Insurance in the Period 2004-2013 
Source: Authors’ research based on HIF TC database 
 
Over the ten year period observed, it is evident that the largest financial expenditures 
refer to the medications for cardiovascular diseases (35%), digestive tract and 
metabolism medications (26%), and medications affecting the nervous system 
(16%). As specified by the second level of the ATC classification, almost 84% of the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 Report on the Realization of Medication Program for the period January-June 2015 (p. 4), Health Insurance 
Fund of Tuzla Canton 
12 Program of other medications includes: medications applied within or under the control of hospital, ampoule 






























those paid by 
citizens)  
2004 105,790,488 1,731,657 13,393,726 355,890 13,749,616 16,664,912 
2005 112,669,255 1,852,401 15,095,216 309,165 15,404,381 18,924,608 
2006 126,318,607 2,328,082 22,212,764 476,627 22,689,391 28,292,882 
2007 148,000,043 2,389,473 24,524,035 789,677 25,313,712 31,712,336 
2008 174,941,709 2,521,478 28,227,413 955,415 29,182,828 36,078,863 
2009 178,171,804 2,226,677 32,888,217 1,339,930 34,228,146 35,663,778 
2010 184,048,334 2,363,402 32,881,082 1,219,381 34,100,463 37,650,112 
2011 192,099,520 2,556,079 37,137,026 633,554 37,770,580 44,845,199 
2012 195,954,753 2,359,443 37,863,086 869,901 38,732,987 42,403,147 
2013 196,299,420 2,377,010 38,768,888 1,109,749 39,878,637 40,150,397 
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total expenditures on medications cover the ten leading groups of medications 
(Table 4), including those for the treatment of hypertension, diabetes, asthma, and 
so on. 
 
Table 4. Financial Costs for Medications in the 10 Leading Groups by ATC Classification in 
2013  
Year 2013 
ATC Group of medications Amount in BAM % 
C09 Agents acting on the rennin-angiotensin system 8,766,544 22.61 
A10 Drugs used in diabetes 7,328,994 18.90 
R03 Drugs for obstructive airway diseases 3,407,972 8.79 
N06 Psychoanaleptics 3,051,384 7.87 
A02 Drugs for acid related disorders 2,209,906 5.70 
J01 Antibacterial drugs 2,178,272 5.62 
C07 Beta blocking agents 2,091,092 5.39 
N05 Psycholeptics 1,326,363 3.42 
C08 Calcium channel blockers 1,118,142 2.88 
N03 Antiepileptics 1,053,397 2.72 
 Ten leading groups of medications in total 32,532,066 83.91 
 Year total 38,768,888 100.00 
 Source: Authors' research based on HIF TC database 
 
The ten leading medications in terms of the resources charged to HIF TC make 
42% of the total value and 27% of the total number of prescriptions. The most 
frequent medication prescribed by family doctors in Tuzla Canton is “Enalapril” for 
hypertension treatment with the average value per prescription of BAM 18 (Table 
5). Out of ten leading medications in terms of financial expenditure, the most 
expensive is “Insulin glargin” (BAM 126 per prescription), which is prescribed for all 
types of diabetes. Within all the medications in the positive list, the medication with 
the highest financial value per prescription is “Ciklosporin”, prescribed to patients 
for the prevention of transplant rejection (BAM 283 per prescription on average). 
These facts depend primarily on medication prices which is why the real 
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Table 5. Ten Leading Medications in 2013 Per Their Total Value Charged to HIF TC 





C09 Enalapril-hidrohlortiazid Hypertension 2,574,774 6.64 140,153 5.90 18 
C10 Lizinopril-hidrohlortiazid Hypertension 2,076,581 5.36 112,219 4.72 19 
R03 Salmeterol+flutikazon 
Obstructive 
airway diseases 1,842,592 4.75 21,715 0.91 85 
A10 Inzulin aspart All types of diabetes 1,822,633 4.70 18,286 0.77 100 
A02 Pantoprazol Gastric and duodenal ulcers 1,402,931 3.62 60,428 2.54 23 
A10 Inzulin glargin All types of diabetes 1,382,965 3.57 11,011 0.46 126 
N06 Paroksetin Depression 1,346,954 3.47 46,563 1.96 29 
C07 Karvedilol Hypertension 1,295,488 3.34 100,546 4.23 13 
A10 Inzulin humani All types of diabetes 1,214,310 3.13 18,606 0.78 65 
A10 Metformin Diabetes 1,176,392 3.03 119,034 5.01 10 
 
Ten leading 
medications  16,135,618 41.62 648,561 27.28 25 
 TOTAL  38,768,888 100.00 2,377,010 100.00 16 
Source: Authors' research based on HIF TC database 
 
In 2013, the medications for the cardiovascular system made somewhat less than a 
half (46.81%) of all the prescriptions issued during that year and they cost almost 
BAM 14 million. The increased consumption is further confirmed by the fact that 
the expenditures for these medications in 2013 were by BAM 400,000 higher that 
the expenditures for the entire program of medications charged to HIF TC ten years 
ago. Among the ten most often prescribed medications there are seven of them for 
the treatment of hypertension. Some 40% of all the prescriptions realized in 2013 
were for these medications, which makes 34% of the total value charged to HIF TC. 
 
Medications for the treatment of diabetes are also an important segment of the 
financial consumption of medications charged to HIF TC. This is confirmed by the 
fact that the value of these medications grew on average by 15.5% in the period 
2004-2013. These medications make 10% of the total amount charged to HIF TC 
and 19% of the total number of prescriptions realized in 2013. On average, every 
patient uses 15 prescriptions a year, with the average value of BAM 470 per patient, 
which is significantly higher than in 2004 when this amount was BAM 267 per 
patient. On the whole, medication consumption matches the morbidity data for the 
territory of Tuzla Canton.  
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Concluding Remarks 
 
Besides a number of problems evident in the inefficient healthcare system and public 
spending control, irrational use of medications that directly reflects on the financial 
burden of healthcare system economy is one of the burning issues if not the most 
important one. When health spending reaches a certain level, it is difficult to return 
it to the previous values as it increases year after year. It is difficult to reduce health 
spending but it can be constantly monitored and gradually controlled.  
 
The analysis of the data presented in the paper leads to the conclusion that the key 
problem of the healthcare sector in BiH is its sustainable financing which is 
primarily evident in the lack of appropriate system of collection of financial resources 
and in the lack of a transparent system for monitoring health spending. The core of 
the problem might be found in the way BiH is organized as a state and in its 
fragmentation to centralized RS, decentralized F BiH, and Brčko District, with 
various legal regulations that complicate successful conduct of fiscal policy. The 
situation is even more complicated by the fact that every entity has its own health 
insurance fund that operates with difficulties due to the finance-related problems but 
also due to accumulated arrears. In addition, serious problems of BiH healthcare 
system are certain inequalities in terms of exercising the right to healthcare. In the 
long term, the healthcare system organized in this way shall not survive; the collected 
resources are almost always limited while the demand for healthcare services 
surpasses the available funds. There are no new sources of financing and the 
collection of regular revenue is problematic, which means that the time has come to 
implement whole scale reforms aimed at improving the conditions under which the 
healthcare system functions. It is not yet known when these changes might happen 
but something can be done regardless of the fact that there is no political will at the 
moment for any changes. In the situations when we cannot change the existing 
financing models, we can start with a better control of the ways in which the 
collected resources are spent and medication consumption is precisely the segment of 
health spending which can be controlled and rationalized in a simple way. 
 
The rational consumption of medications means giving a patient the appropriate 
medication in the dosage defined by the clinical and individual needs so that the 
patient and the society as a whole pay the lowest possible price. It is not known to 
what extent these principles are followed in terms of dosage specification based on 
patient’s clinical and individual needs but the research results indicate that in BiH 
both the society and the patients pay medications at a too high price. Sometimes, the 
state itself contributes to over consumption of medications through its inactive and 
bad decisions in legislation and executive power. Instead of serving solely to limit the 
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unnecessary consumption, the laws regulating manufacture, trade and price of 
medications, their additions on health insurance lists, sales regime, patients’ 
participation in the price, and marketing often stimulate consumption. The 
pharmaceutical industry might be seen as one of the main drives of medication 
consumption and its constant growth. The role of pharmaceutical industry has 
changed over history − while in the past the cure was sought for as many diseases as 
possible, it seems as if today the goal is to find as many diseases as possible for the 
cure.  
 
Primary healthcare is also the segment where increased medication consumption 
emerges. Although the concept of primary healthcare is as a rule devised so as to 
unburden secondary healthcare, this seems not to be the case. Physicians in primary 
healthcare face crowd at their practices, work under pressure, and so on. Also, 
consulting clinical pharmacologists reduces over issuance of medication prescription, 
which consequently results in reduced expenditure for medications. Drug abuse 
seems to be one of the reasons for the increased medication consumption. Nowadays 
every home obviously has certain medications in stock, which are used at one’s own 
opinion. 
 
Increased financial expenditure on medication is affected by medication selling 
prices. While some of the surrounding countries have zero VAT rate on medications, 
with 17% VAT rate BiH is one of the most expensive countries in terms of 
medication prices. This is caused by a small market, many levies, rigid law on 
medicinal products and medical devices, and high pharmacy margins which directly 
affect patients’ budgets. The Rulebook on Price Monitoring, Calculating Medication 
Prices and Reporting on Medication Prices in BiH would be an excellent instrument 
of medication control in BiH. The VAT rate is not the only reason for expensive 
medications in the country as medication prices generally vary in the entities, which 
is probably caused by the decentralized system of medication procurement. 
However, some medications are as much as 400% more expensive than in the 
neighboring Serbia, where many BiH citizens buy medications, which confirms the 
allocation of financial resources outside BiH borders and the potential grey market 
(medication smuggling). What is equally important is the need for the establishment 
of the unique system of medication consumption monitoring on a state level based 
on the ATC/DDD methodology, with the aim of gaining the real insight into 
medication consumption so as to identify the causes and consequences of irrational 
consumption. Also, constant education in the field of health economics is needed as 
raising awareness of the budget limitations in the healthcare system is an extremely 
long and difficult process for both patients and healthcare workers. This can only be 
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done by appropriate education of the general public, healthcare workers, creators of 
healthcare policies, and so on. 
 
The presented theoretical elaboration of the problem as well as the empirical research 
conducted in BiH and Tuzla Canton, as the most populated BiH canton, indicate 
that the central research hypothesis is accepted. Future research interest might focus 
of monitoring medication consumption within hospital capacities, since it is not 
monitored analytically, in order to establish the real consumption and define 
potential causes of (non)increase in the use of medications charged to health 
insurance. Besides, it would be interesting to conduct a research into the usage of 
medications from the aspect of physician habits related to medication prescription, 
with a particular emphasis on the problems they face in their practice. One might 
find useful to investigate the perception and habits of the patients as those who 
consume medications, in order to detect important factors that influence increased 
demand for medications and establish the actual financial burden imposed on 
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